|
|||||
|
|
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato‐oncology clinic |
|
| Authors: | Ayelet Ollech MD Salomon M. Stemmer MD Sharon Merims MD Michal Lotem MD Aron Popovtzer MD Daniel Hendler MD Emmilia Hodak MD Elena Didkovsky MD Iris Amitay‐Laish MD |
| Affiliation: | 1. Department of Dermatology, Rabin Medical Center, Petach Tikva, Israel;2. Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel;3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;4. Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel;5. Department of Pathology, Rabin Medical Center, Petach Tikva, Israel |
| Abstract: | |
| Keywords: | |